Still病患者血清细胞因子水平迈向精准医学:托珠单抗随机对照试验的亚组分析
该研究为52周随机双盲安慰剂对照托珠单抗试验的亚组分析,纳入26例Still病患者(托珠单抗组13例、安慰剂组13例),定期检测多种血清细胞因子。结果显示托珠单抗起效局限于IL-6信号通路,无应答者基线IFN-γ和IL-1β显著高于应答者,第52周IFN-γ和IL-18仍保持高水平,提示无应答者细胞因子谱以IFN-γ轴为核心。
要点
- 托珠单抗治疗前IL-6水平与DAS28相关(r=0.67,P<0.01)。
- 无应答者基线IFN-γ和IL-1β显著高于应答者。
- 第52周无应答者IFN-γ和IL-18水平仍显著高于应答者。
核心结论
- 托珠单抗在Still病中的作用局限于IL-6信号通路,未应答者呈现以IFN-γ轴为核心的独特细胞因子谱,为个体化治疗策略提供线索。
研究设计与样本
- 此为52周随机双盲安慰剂对照托珠单抗试验的亚组分析,共纳入26例Still病患者(托珠单抗组13例、安慰剂组13例),定期检测多种血清细胞因子水平。
主要发现
- 托珠单抗治疗前IL-6水平与DAS28相关(r=0.67,P<0.01),IL-1β、IL-6和IL-18水平与全身特征评分趋于相关(r=0.33,P=0.09;r=0.38,P=0.05;r=0.40,P=0.04)。
- 托珠单抗启用后IL-6和IL-6受体水平显著升高,其他细胞因子与安慰剂组相比无显著差异。
- 无应答者基线IFN-γ和IL-1β水平显著高于应答者(28.49 vs 5.65 pg/ml,P=0.03;0.26 vs 0.04 pg/ml,P=0.048)。
- 第52周无应答者IFN-γ和IL-18水平仍保持高位(15.56 vs 7.03 pg/ml,P=0.02;5924 vs 392 pg/ml,P=0.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To predict the efficacy of IL-6 inhibition in patients with Still's disease by analysing inflammatory cytokine profiles before and during an IL-6 receptor inhibitor therapy. METHODS: This is a subanalysis of the 52-week, randomized, double-blind, placebo-controlled trial of tocilizumab, an IL-6 receptor inhibitor, in patients with Still's disease. Multiple serum cytokine levels were measured regularly, and their pattern and profiles were analysed based on the response to tocilizumab. RESULTS: A total of 26 patients (13 in the tocilizumab group and 13 in the placebo group) were enrolled. Before tocilizumab treatment, IL-6 levels were correlated with DAS with 28 joints (r = 0.67, P < 0.01), and IL-1β, IL-6 and IL-18 levels tended to be correlated with systemic feature score (r = 0.33, P = 0.09; r = 0.38, P = 0.05; r = 0.40, P = 0.04, respectively). IL-6 and IL-6 receptor levels were significantly elevated after tocilizumab initiation, while the other cytokines showed no significant difference compared with placebo. Baseline levels of IFN-γ and IL-1β were significantly higher in non-responders compared with responders (28.49 vs 5.65 pg/ml, P = 0.03; 0.26 vs 0.04 pg/ml, P = 0.048), and IFN-γ and IL-18 levels at week 52 remained high in non-responders (15.56 vs 7.03 pg/ml, P = 0.02; 5924 vs 392 pg/ml, P = 0.02). CONCLUSIONS: The effect of tocilizumab is limited to the IL-6 signalling pathway in Still's disease. Patients who did not respond to tocilizumab exhibited distinct cytokine profiles that pivot the IFN-γ axis. These findings highlight the role of IL-6 inhibition in Still's disease and shed light on its personalized treatment strategies. CLINICAL TRIAL REGISTRATION NUMBER: UMIN Clinical Trials Registry; UMIN000012987.
引用
- Suzuki K, Kameda H, Ikeda K, et al. Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab. Rheumatology (Oxford). 2025. PMID: 40516928. doi:10.1093/rheumatology/keaf254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。